JP2017509624A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017509624A5 JP2017509624A5 JP2016556709A JP2016556709A JP2017509624A5 JP 2017509624 A5 JP2017509624 A5 JP 2017509624A5 JP 2016556709 A JP2016556709 A JP 2016556709A JP 2016556709 A JP2016556709 A JP 2016556709A JP 2017509624 A5 JP2017509624 A5 JP 2017509624A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- patient
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954094P | 2014-03-17 | 2014-03-17 | |
| US61/954,094 | 2014-03-17 | ||
| US201462025400P | 2014-07-16 | 2014-07-16 | |
| US62/025,400 | 2014-07-16 | ||
| US201462043182P | 2014-08-28 | 2014-08-28 | |
| US62/043,182 | 2014-08-28 | ||
| EP15305293.1 | 2015-02-26 | ||
| EP15305293 | 2015-02-26 | ||
| PCT/US2015/020564 WO2015142668A1 (en) | 2014-03-17 | 2015-03-13 | Methods for reducing cardiovascular risk |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020097344A Division JP2020143156A (ja) | 2014-03-17 | 2020-06-04 | 心血管リスクを低減させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017509624A JP2017509624A (ja) | 2017-04-06 |
| JP2017509624A5 true JP2017509624A5 (enExample) | 2018-04-12 |
Family
ID=52648962
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556709A Pending JP2017509624A (ja) | 2014-03-17 | 2015-03-13 | 心血管リスクを低減させる方法 |
| JP2022116854A Pending JP2022141868A (ja) | 2014-03-17 | 2022-07-22 | 心血管リスクを低減させる方法 |
| JP2024115429A Pending JP2024147744A (ja) | 2014-03-17 | 2024-07-19 | 心血管リスクを低減させる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116854A Pending JP2022141868A (ja) | 2014-03-17 | 2022-07-22 | 心血管リスクを低減させる方法 |
| JP2024115429A Pending JP2024147744A (ja) | 2014-03-17 | 2024-07-19 | 心血管リスクを低減させる方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150284473A1 (enExample) |
| EP (2) | EP4403213A3 (enExample) |
| JP (3) | JP2017509624A (enExample) |
| KR (3) | KR20220157516A (enExample) |
| CN (3) | CN114558129A (enExample) |
| AU (3) | AU2015231713B2 (enExample) |
| CA (1) | CA2942549A1 (enExample) |
| EA (1) | EA039310B1 (enExample) |
| ES (1) | ES2978990T3 (enExample) |
| HU (1) | HUE066839T2 (enExample) |
| IL (1) | IL304491B1 (enExample) |
| MX (1) | MX380767B (enExample) |
| PL (1) | PL3119810T3 (enExample) |
| WO (1) | WO2015142668A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| BRPI1011883A2 (pt) | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| CA2825778A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW201534324A (zh) | 2013-06-07 | 2015-09-16 | Sanofi Sa | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| US20170198059A1 (en) * | 2014-07-14 | 2017-07-13 | Amgen Inc. | Crystalline antibody formulations |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| AU2015289617B2 (en) * | 2014-07-16 | 2021-04-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| EP3197492A1 (en) | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
| EA201890519A1 (ru) | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| JOP20190112A1 (ar) * | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
| US10600502B2 (en) * | 2016-12-20 | 2020-03-24 | Astrazeneca Uk Ltd. | Systems and methods for dispensing a statin medication over the counter |
| US10329620B2 (en) | 2017-01-12 | 2019-06-25 | Cardioforecast Ltd. | Methods and kits for treating cardiovascular disease |
| US11325945B2 (en) | 2017-04-12 | 2022-05-10 | Cadila Healthcare Limited | Peptide based PCSK9 vaccine |
| IL277127B2 (en) * | 2018-03-06 | 2025-11-01 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
| JP7513533B2 (ja) * | 2018-07-02 | 2024-07-09 | アブセントラ，エルエルシー | リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療 |
| US20220362200A1 (en) * | 2018-08-17 | 2022-11-17 | Craig Granowitz | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject |
| MA50490A (fr) | 2018-09-24 | 2020-09-02 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| TWI887293B (zh) * | 2019-11-07 | 2025-06-21 | 美商麥迪紐有限責任公司 | 用於治療心血管疾病之內皮脂酶抗體 |
| CA3160676A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| JP2023501745A (ja) * | 2019-11-18 | 2023-01-18 | エーディー ファーマシューティカルズ カンパニー，リミティド | 抗ｐｃｓｋ９抗体及びその使用 |
| CA3180222A1 (en) * | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| CN114848849B (zh) * | 2022-04-25 | 2023-11-17 | 南方科技大学 | Pcsk9蛋白抑制剂在治疗心血管疾病中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CA2825778A1 (en) * | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
-
2015
- 2015-03-13 CN CN202210141133.5A patent/CN114558129A/zh active Pending
- 2015-03-13 EA EA201691847A patent/EA039310B1/ru unknown
- 2015-03-13 PL PL15712241.7T patent/PL3119810T3/pl unknown
- 2015-03-13 AU AU2015231713A patent/AU2015231713B2/en active Active
- 2015-03-13 CN CN202210141115.7A patent/CN114642661A/zh active Pending
- 2015-03-13 KR KR1020227039740A patent/KR20220157516A/ko not_active Ceased
- 2015-03-13 EP EP24160083.2A patent/EP4403213A3/en active Pending
- 2015-03-13 EP EP15712241.7A patent/EP3119810B1/en active Active
- 2015-03-13 WO PCT/US2015/020564 patent/WO2015142668A1/en not_active Ceased
- 2015-03-13 CN CN201580024259.2A patent/CN106794244A/zh active Pending
- 2015-03-13 KR KR1020167028383A patent/KR20160132459A/ko not_active Ceased
- 2015-03-13 HU HUE15712241A patent/HUE066839T2/hu unknown
- 2015-03-13 KR KR1020247040556A patent/KR20250006995A/ko active Pending
- 2015-03-13 ES ES15712241T patent/ES2978990T3/es active Active
- 2015-03-13 US US14/657,192 patent/US20150284473A1/en not_active Abandoned
- 2015-03-13 JP JP2016556709A patent/JP2017509624A/ja active Pending
- 2015-03-13 IL IL304491A patent/IL304491B1/en unknown
- 2015-03-13 CA CA2942549A patent/CA2942549A1/en active Pending
- 2015-03-13 MX MX2016011975A patent/MX380767B/es unknown
-
2021
- 2021-02-19 AU AU2021201118A patent/AU2021201118A1/en not_active Abandoned
- 2021-10-19 US US17/504,921 patent/US20220144969A1/en not_active Abandoned
-
2022
- 2022-07-22 JP JP2022116854A patent/JP2022141868A/ja active Pending
-
2024
- 2024-07-19 JP JP2024115429A patent/JP2024147744A/ja active Pending
- 2024-07-31 AU AU2024205254A patent/AU2024205254A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Expert consensus on the use of human serum albumin in critically ill patients | |
| JP2017506626A5 (enExample) | ||
| Soran et al. | Hypercholesterolaemia–practical information for non-specialists | |
| Rienstra et al. | Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial | |
| Teramoto et al. | Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with Statins–ODYSSEY JAPAN randomized controlled Trial– | |
| JP2021515772A5 (enExample) | ||
| Farnier et al. | Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials | |
| JP2017160208A5 (enExample) | ||
| JP2025011161A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2017528427A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| JP2012528796A5 (enExample) | ||
| Mercer et al. | Diabetes mellitus and the heart | |
| Ito | Dyslipidemia: management using optimal lipid-lowering therapy | |
| JP2014516953A5 (enExample) | ||
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| JP2019507781A5 (enExample) | ||
| JP2016538277A5 (enExample) | ||
| CN107922507A (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| JP2017535551A5 (enExample) | ||
| JP7193455B2 (ja) | 心血管状態におけるインスリンデグルデク | |
| JP2020143156A5 (enExample) | ||
| Coghlan et al. | Selexipag in the management of pulmonary arterial hypertension: an update |